Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus

Visser, E.K.; Edholm, David; Smithers, B. Mark; Burmeister, Bryan; Walpole, Euan; Gotley, D. C.; Joubert, Warren; Atkinson, Victoria; Mai, Tao; Thomas, Janine; Barbour, Andrew P.

doi:10.1002/jso.25089

Cited by 23 publications

(28 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serous epithelial ovarian carcinoma has a very low five-year survival rate of 42% for stage III and 26% for stage IV [7] with a 19% recurrence rate [8]. Esophageal adenocarcinoma represents a similarly low five-year survival rate of 33% to 44% [9], depending on the treatment used, and can result in a recurrence rate as high as 43.2% [10].…”

Section: Introductionmentioning

confidence: 99%

The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner

Rowe¹,

Cheng²,

Ly³

et al. 2018

Plasma

View full text Add to dashboard Cite

Abstract:To determine appropriate treatment doses of cold atmospheric plasma (CAP), the Canady Helios Cold Plasma Scalpel was tested across numerous cancer cell types including renal adenocarcinoma, colorectal carcinoma, pancreatic adenocarcinoma, ovarian adenocarcinoma, and esophageal adenocarcinoma. Various CAP doses were tested consisting of both high (3 L/min) and low (1 L/min) helium flow rates, several power settings, and a range of treatment times up to 5 min. The impact of cold plasma on the reduction of viability was consistently dose-dependent; however, the anti-cancer capability varied significantly between cell lines. While the lowest effective dose varied from cell line to cell line, in each case an 80-99% reduction in viability was achievable 48 h after CAP treatment. Therefore, it is critical to select the appropriate CAP dose necessary for treating a specific cancer cell type.

show abstract

Section: Introductionmentioning

confidence: 99%

The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner

Rowe¹,

Cheng²,

Ly³

et al. 2018

Plasma

View full text Add to dashboard Cite

show abstract

“…Koch compared preoperative chemotherapy with the CROSS regimen for patients with adenocarcinoma of the esophagus and EGJ: 60-month DFS for patients treated with NACRT was 8% [15], similar to that obtained in our experience. Better results in terms of DFS were obtained in other studies [10][11][12][13][14].…”

Section: Discussionmentioning

confidence: 56%

Does Pathological Stage and Nodal Involvement Influence Long Term Oncological Outcomes after CROSS Regimen for Adenocarcinoma of the Esophagogastric Junction? A Multicenter Retrospective Analysis

Pascale

Valmasoni

Weindelmayer

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…However, although chemotherapy may provide local control, studies indicate no difference in survival. 41–44…”

Section: Discussionmentioning

confidence: 99%

Precision Surgical Therapy for Adenocarcinoma of the Esophagus and Esophagogastric Junction

Rice

Lü

Ishwaran

et al. 2019

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Introduction: To facilitate initial clinical decision whether to use esophagectomy alone or neoadjuvant therapy in surgical care for individual patients with adenocarcinoma of the esophagus and esophagogastric junction—information not available from randomized trials—a machine-learning analysis was performed using worldwide real-world data on patients undergoing different therapies for this rare adenocarcinoma. Methods: Using random forest technology in a sequential analysis, we 1) identified eligibility for each of 4 therapies among 13,365 patients: esophagectomy alone (n=6,649), neoadjuvant therapy (n=4,706), esophagectomy and adjuvant therapy (n=998), and neoadjuvant and adjuvant therapy (n=1,022); 2) performed survival analyses incorporating interactions of patient and cancer characteristics with therapy; 3) determined optimal therapy as that predicted to maximize lifetime within 10 years (restricted mean survival time, RMST) for each patient; and 4) compared lifetime gained from optimal versus actual therapies. Results: Actual therapy was optimal in 61% of those receiving esophagectomy alone; neoadjuvant therapy was optimal for 36% receiving neoadjuvant therapy. Many patients were predicted to benefit from postoperative adjuvant therapy. Total RMST for actual therapy received was 58,825 years. Had patients received optimal therapy, total RMST was predicted to be 62,982 years, a 7% gain. Conclusions: Average treatment effect for adenocarcinoma of the esophagus yields only crude evidence-based therapy guidelines. However, patient response to therapy is widely variable, and survival after data-driven predicted optimal therapy often differs from actual therapy received. Therapy must address an individual patient’s cancer and clinical characteristics to provide precision surgical therapy for adenocarcinoma of the esophagus and esophagogastric junction.

show abstract

Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus

Cited by 23 publications

References 28 publications

The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner

The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner

Does Pathological Stage and Nodal Involvement Influence Long Term Oncological Outcomes after CROSS Regimen for Adenocarcinoma of the Esophagogastric Junction? A Multicenter Retrospective Analysis

Precision Surgical Therapy for Adenocarcinoma of the Esophagus and Esophagogastric Junction

Contact Info

Product

Resources

About